Centralized HIV-1 envelope immunogens and neutralizing antibodies

Current HIV Research

Volumn 5, Issue 6, 2007, Pages 572-577

  Gao, Feng ^a   Liao, Hua Xin ^a   Hahn, Beatrice H ^b   Letvin, Norman L ^c   Korber, Bette T ^d,e   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e SANTA FE INSTITUTE   (United States)

Author keywords

Ancestor; Consensus; Neutralizing antibodies; Vaccine; Variation

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGENICITY; B LYMPHOCYTE; CLINICAL TRIAL; DNA IMMUNIZATION; ENVELOPE GENE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; REVIEW; STRAIN DIFFERENCE; T LYMPHOCYTE; VIRUS STRAIN; VIRUS VIRULENCE;

AIDS VACCINES; CONSENSUS SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, ENV; HIV-1; HUMANS; RECEPTORS, CCR5; VACCINES, SYNTHETIC;

EID: 38949176103     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207782418498     Document Type: Review

References (57)

1. Alam SM. McAdams M. Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BE (2007). The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. Journal of Immunology. 178: 4424-4435.
2. Beck Z, Karasavvas N, Tong J, Matyas GR, Rao M, Alving CR. (2007). Calcium modulation of monoclonal antibody binding to phosphatidylinositol phosphate. Biochemical and Biophysical Research Communications. 354: 747-751.
3. Brave A, Ljungberg K, Boberg A, Rollman E, Engstrom G, Hinkula J, Wahren B. (2006). Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine. 24: 4524-4526.
4. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. (2004). HIV vaccine design and the neutralizing antibody problem. Nature Immunology. 5: 233-236.
5. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS. (2007). Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 25: 4085-4092.
6. Chakrabarti BY, Kong WP, Wu BY, Yang ZY, Friborg J, Ling X, King SR, Montefiori DC, Nabel GJ. (2002). Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. Joumal of Virology 76: 5357-5368.
7. Chakrabarti BK, Ling Y, Yang ZY, Montefiori DC, Panet A, Kong WP, Welcher B: Louder MK, Mascola JR, Nobel GJ.,(2005). Expanded breadth of virus neutralization after immunization with a multiclade envelope. HIV vaccine candidate. Vaccine. 23, 3434-3445.
8. Cho MW, Kim YB, Lev, MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA. (2001). Polyvalent envelope glypoprotein vaccine elicits a broader neutralizing antibody, response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. Journal of Virology. 75: 2224-2234.
9. Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S. Restrepo S, Suschak J, Grazi Ferrari M, Chung HK, Kalyanaraman VS, Markham P, Pal R. (2007). HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology. 366:197-211.
10. Desrosiers RC. (2004). Prospects for an AIDS vaccine. Nature Medicine. 10: 221-223.
11. Doria-Rose NA, Learn GH, Rodrigo AG, Nickle DC, Li F, Mahalanabis M, Hensel MT, McLaughlin S, Edmonson PF, Montefiori D, Barnett SW, Haigwood NL, Mullins JI. (2005). Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. Journal of Virology. 79: 11214-11224.
12. Ellenberger DL, Li B, Lupo LD, Owen SM, Nkengasong J, Kadio-Morokro MS, Smith J, Robinson H, Ackers M, Greenberg A, Folks T, Butera S. (2002). Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology. 302: 155-163.
13. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funk-houser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT. (2007). Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Medicine. 13:100-106.
14. Gao F, Bhattacharya T, Gaschen B, Taylor J, Moore JP, Novitsky V, Yusim K, Lang D, Foley B, Beddows; S, Alam M, Haynes B, Hahn BH, Korber B. (2003). Consensus and Ancestral State HIV Vaccines (Letter). Science. 299: 1517-1518.
15. Gao F. Korber BT, Weaver E, Liao RX, Hahn BH, Haynes BF. (2004). Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Review of Vaccines. 3 Suppl 1: S161-168.
16. Gao E, Weaver EA, Lit Z, Li Y, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu JS, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF. (2005). Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group in consensus envelope glycoprotein. Journal of Virology. 79: 1154-1163.
17. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. (2002). Diversity considerations in HIV-1 vaccine selection. Science. 296: 2354-2360.
18. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. (1997). Passive immunization with a human monoclonal antibody protects hu-PBL- SCID mice against challenge by primary isolates of HIV-1. Nature Medicine. 3: 1389-1393.
19. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ. (2006). Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. Journal of Infectious Diseases. 194: 1650-1660.
20. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 308: 1906-1908.
21. Haynes BF, Ma B, Montefiori DC, Wrin T. Petropoulos CJ, Sutherland, LL, Scearce RM, Denton C, Xia SM, Korber BT, Liao HX. (2006). Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology. 345: 44-55.
22. Haynes BF. Montefiori DC. (2006). Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Review of Vaccines. 5: 347-363.
23. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. (2005). Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Human Antibodies. 14: 59-67.
24. Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou TH, Lu S. (2005). Application of the polyvalent approach to HIV-1 vaccine development. Current Drug Targets - Infectious Disorders. 5: 143-156.
25. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. (2001). Evolutionary and immunological implications of contemporary HIV-1 variation. British Medical Bulletin. 58: 19-42.
26. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Mestecky, Gan F, Haynes BF, Shaw GM, Muldoon M, Korber BT, Hahn BH. (2007). Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 360: 218-234.
27. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Haynes BF, Shaw GM, Korber BT, Hahn BH. (2006). Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology. 352:438-449.
28. Krohn K, Stanescu I, Blazevic V, Vesikari T, Ranki A, Ustav M. (2005). A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes and Infection. 7: 1405-1413.
29. Leitner T, Foley B, Hahn BH, Marx PA, McCutchan F, Mellors JW, Wolinksy S, Korber B. (2006). HIV sequence compendium 2005. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM.
30. Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies ME, Lekutis C, Alroy M, Freed DC, Lord CI, Handt LK, Liu MA, Shiver JW. (1997). Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proceedings of the National Academy of Sciences of the United States of America. 94: 9378-9383.
31. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho 7, Ma BJ, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF. (2006). A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology. 353: 268-282.
32. Lin HH, Gaschen BK, Collie M, El-Fishaway M, Chen Z, Korber BT, Beatrice ST, Zhang L. (2006). Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. Journal of Acquired Immune Deficiency Syndromes. 41: 399-404.
33. Malm M, Rollman E, Usfav M, Hinkula J, Krohn K, Wahren B, Blazevic V. (2005). Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunology. 18: 678-688.
34. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine. 6: 207-210.
35. Mullins JI, Nickle DC, Heath L, Rodrigo AG, Learn GH. (2004). Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Review of Vaccines. 3: S151-159.
36. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, Mullins JI. (2003). Consensus and Ancestral State HIV Vaccines (Letter). Science. 299: 1515-1517.
37. Nickle DC, Rolland M, Jensen MA, Pond SL, Deng W, Seligman M, Heckerman D, Mullins JI, Jojic N. (2007). Coping with viral diversity in HIV vaccine design. PLoS Computational Biology. 3: e75.
38. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, Ndung'u T, Klein I, Chang SY, Peter T, Thior I, Foley, BT, Gaolekwe S, Rybak N, Gaseitsiwe S, Vannberg F, Marlink R, Lee TH, Essex M.,(2002). Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? Journal of Virology. 76: 5435-5451.
39. Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S. (2006). Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology. 348: 341-353.
40. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P. (2005). Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. Journal of Medical Primatology. 34: 226-236.
41. Pantophlet R, Burton DR (2006). 120: target for neutralizing HIV-1 antibodies. Annual Review of Immunology. 24: 739-769.
42. Peeters M, Toure-Kane C, Nkengasong JN. (2003). Genetic diversity of HIV in Africa: impact on diagnosis, treatment vaccine development and trials. AIDS. 17: 2547-2560.
43. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, Kalish ML, Shaw GM, Allen S, Hahn BH, Gao F, Characterization tUaNNfHIa. (2001). Near full-length clones and reference sequences for subtype C isolates of HIV-1 from three different continents. AIDS Research and Human Retroviruses. 17: 161-168.
44. Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, Heath L, Weiner D, Mullins JI. (2007). Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. Journal of Virology. 81: 8507-8514.
45. Sanchez-Martinez S, Lorizate M, Hermann Y, Kunert R, Basanez G, Nieva JL. (2006). Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Letters. 580: 2395-2399.
46. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL. (2006). Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Research and Human Retroviruses. 22: 998-1006.
47. Santra S, Korber B, Muldoon M, Barouch D, Nabel GJ, Montefiori DC, Liao HX, Parks P, Hahn BH, Gao F, Haynes B, Letvin NL. (2007). Vaccines expressiong a centralized HIV-1 envelope sequence generate broadly reactive cellular and humoral immune respnoses in morkeys. Submitted
48. Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, Letvin NL, Mascola JR. (2007). Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology. 367: 175-186.
49. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, Sambor A, Chakrabarti BK, Huang Y, Bailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL. (2005). Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. Journal of Virology. 79: 2956-2963.
50. Sharp PM. (2002). Origins of human virus diversity. Cell. 108: 305-312.
51. Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, Kent SJ, Gao K, Medveckzy J, Ffrench RA, Ramshaw IA. (2005). Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine. 23: 4647-4657.
52. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP. (2003). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Medicine. 9: 343-346.
53. Vidal N, Peeters.M, Mulanga-Kabeya C, Nzilambi N, Robertson D, Ilunga W, Sema H, Tshimanga K, Bongo B, Delaporte E. (2000). Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. Journal of Virology. 74: 10498-10507.
54. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. (2006). Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 350: 34-47.
55. Weaver EA, Lu Z,. Camacho ZT, Moukdar F, Liao HX, Ma BJ. Muldoon M, Theiler J, Nabel GJ, Letvin NL, Korber BT, Hahn 3H, Haynes BF, Gao F. (2006). Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. Journal of Virology. 80: 6745-6756.
56. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, Chigaev A, Detours V, Korber BT. (2002). Clustering patterns of cytotoxic T-lymphocyte epitopes in human immnuodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. Journal of Virology. 76: 8757-8768.
57. Zhang PF, Chain F, Dong M, Choudhary A, Bourna P, Zhang Z, Shao Y, Feng YR, Wang L, Mathy N, Voss G, Broder CC, Quinnan GV, Jr. (2007). Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proceedings of the National Academy of Sciences of the United States of America. 104: 10193-10198.